Uzbekistan To Implement Large Pharma Projects
Executive Summary
Uzbekistan is the most populous country in Central Asia with 36 million people. The country has the only plant in Central Asia specializing in insulin production for the treatment of diabetes. Uzbek authorities aim to develop 90 pharma projects worth $1.2bn by 2026.
You may also be interested in...
Krka Welcomes ‘Highest Six-Month EBIT In Company’s History’
Slovenian firm and significant Eastern European and Central Asian player Krka has reported encouraging preliminary financial results for the first six months of the year, ahead of the imminent publication of its complete financial results.
China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms
China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.
China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms
China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.